Meningeal inflammation increases artemether concentrations in cerebrospinal fluid in Papua New Guinean children treated with intramuscular artemether

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 5027-5033

  Manning, Laurens ^a   Laman, Moses ^a,b   Page Sharp, Madhu ^c   Salman, Sam ^a   Hwaiwhanje, Ilomo ^d   Morep, Namar ^b   Siba, Peter ^b   Mueller, Ivo ^e,f   Karunajeewa, Harin A ^g   Davis, Timothy M E ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^c CURTIN UNIVERSITY   (Australia)

^d Modilon Hospital   (Papua New Guinea)

^e WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^f CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^g WESTERN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER; DIHYDROARTEMISININ;

ARTICLE; CEREBROSPINAL FLUID; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; LEUKOCYTE COUNT; LUMBAR PUNCTURE; MALARIA FALCIPARUM; MALE; MENINGITIS; PAPUA NEW GUINEA; PRESCHOOL CHILD; PRIORITY JOURNAL;

ARTEMISININS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INJECTIONS, INTRAMUSCULAR; MALARIA, FALCIPARUM; MALE; MENINGES; PAPUA NEW GUINEA; PROSPECTIVE STUDIES;

EID: 80054703404     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00375-11     Document Type: Article

References (53)

1. Ahn, J. E., M. O. Karlsson, A. Dunne, and T. M. Ludden. 2008. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J. Pharmacokinet. Pharmacodyn. 35:401-421.
2. Anderson, B. J., and N. H. Holford. 2008. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48:303-332. (Pubitemid 351738156)
3. Anga, G., et al. 2010. The aetiology, clinical presentations and outcome of febrile encephalopathy in children in Papua New Guinea. Ann. Trop. Paediatr. 30:109-118.
4. Barnes, K. I., W. M. Watkins, and N. J. White. 2008. Antimalarial dosing regimens and drug resistance. Trends Parasitol. 24:127-134.
5. Batty, K. T., et al. 1996. Selective high-performance liquid chromatographic determination of artesunate and alpha- and beta- dihydroartemisinin in patients with falciparum malaria. J. Chromatogr. B Biomed. Appl. 677:345-350. (Pubitemid 26106005)
6. Berkley, J. A., A. C. Versteeg, I. Mwangi, B. S. Lowe, and C. R. Newton. 2004. Indicators of acute bacterial meningitis in children at a rural Kenyan district hospital. Pediatrics 114:e713-e719. (Pubitemid 41754904)
7. Bethell, D., et al. 2010. Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. Clin. Infect. Dis. 51:e105-e114.
8. Brewer, T. G., et al. 1994. Neurotoxicity in animals due to arteether and artemether. Trans. R. Soc. Trop. Med. Hyg. 88(Suppl. 1):S33-S36. (Pubitemid 24206484)
9. Davis, T. M., et al. 2003. Penetration of dihydroartemisinin into cerebrospinal fluid after administration of intravenous artesunate in severe falciparum malaria. Antimicrob. Agents Chemother. 47:368-370. (Pubitemid 36070387)
10. Davis, T. M., et al. 1997. Severe falciparum malaria with hyperparasitaemia treated with intravenous artesunate. Med. J. Aust. 166:416-418. (Pubitemid 27187085)
11. Dondorp, A., F. Nosten, K. Stepniewska, N. Day, and N. White. 2005. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366:717-725. (Pubitemid 41207233)
12. Dondorp, A. M., et al. 2010. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 376:1647-1657.
13. Dondorp, A. M., et al. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361:455-467.
14. Efferth, T., and B. Kaina. 2010. Toxicity of the antimalarial artemisinin and its derivatives. Crit. Rev. Toxicol. 40:405-421.
15. Elias, Z., E. Bonnet, B. Marchou, and P. Massip. 1999. Neurotoxicity of artemisinin: possible counseling and treatment of side effects. Clin. Infect. Dis. 28:1330-1331. (Pubitemid 29272820)
16. Ette, E. I., A. W. Kelman, C. A. Howie, and B. Whiting. 1995. Analysis of animal pharmacokinetic data: performance of the one point per animal design. J. Pharmacokinet. Biopharm. 23:551-566. (Pubitemid 26155333)
17. Franco-Paredes, C., R. Dismukes, D. Nicolls, and P. E. Kozarsky. 2005. Neurotoxicity due to antimalarial therapy associated with misdiagnosis of malaria. Clin. Infect. Dis. 40:1710-1711. (Pubitemid 40720835)
18. Genovese, R. F., and D. B. Newman. 2008. Understanding artemisinin-induced brainstem neurotoxicity. Arch. Toxicol. 82:379-385.
19. German, P. I., and F. T. Aweeka. 2008. Clinical pharmacology of artemisininbased combination therapies. Clin. Pharmacokinet. 47:91-102.
20. Gordi, T., and E. I. Lepist. 2004. Artemisinin derivatives: toxic for laboratory animals, safe for humans? Toxicol. Lett. 147:99-107. (Pubitemid 38130178)
21. Hien, T. T., et al. 2003. Neuropathological assessment of artemether-treated severe malaria. Lancet 362:295-296. (Pubitemid 36936843)
22. Kager, P. A., M. J. Schultz, E. E. Zijlstra, B. van den Berg, and C. J. van Boxtel. 1994. Arteether administration in humans: preliminary studies of pharmacokinetics, safety and tolerance. Trans. R. Soc. Trop. Med. Hyg. 88(Suppl. 1):S53-S54. (Pubitemid 24206490)
23. Karunajeewa, H. A., et al. 2008. A trial of combination antimalarial therapies in children from Papua New Guinea. N. Engl. J. Med. 359:2545-2557.
24. Karunajeewa, H. A., et al. 2006. Artesunate suppositories versus intramuscular artemether for treatment of severe malaria in children in Papua New Guinea. Antimicrob. Agents Chemother. 50:968-974. (Pubitemid 43327802)
25. Kissinger, E., et al. 2000. Clinical and neurophysiological study of the effects of multiple doses of artemisinin on brain-stem function in Vietnamese patients. Am. J. Trop. Med. Hyg. 63:48-55. (Pubitemid 32423094)
26. Laman, M., I. Hwaihwanje, T. M. Davis, and L. Manning. 2010. Cryptococcal meningitis in immunocompetent Papua New Guinean children. Trop. Doct. 40:61-63.
27. Laman, M., et al. 2010. Lumbar puncture in children from an area of malaria endemicity who present with a febrile seizure. Clin. Infect. Dis. 51:534-540.
28. Li, Q. G., et al. 2002. Neurotoxicity and efficacy of arteether related to its exposure times and exposure levels in rodents. Am. J. Trop. Med. Hyg. 66:516-525.
29. Makani, J., et al. 2003. Admission diagnosis of cerebral malaria in adults in an endemic area of Tanzania: implications and clinical description. QJM 96:355-362. (Pubitemid 36592707)
30. Matuszewski, B. K., M. L. Constanzer, and C. M. Chavez-Eng. 2003. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 75:3019-3030. (Pubitemid 36830428)
31. McCall, M. B., A. J. Beynon, E. A. Mylanus, A. J. van der Ven, and R. W. Sauerwein. 2006. No hearing loss associated with the use of artemetherlumefantrine to treat experimental human malaria. Trans. R. Soc. Trop. Med. Hyg. 100:1098-1104. (Pubitemid 44464017)
32. Miller, L. G., and C. B. Panosian. 1997. Ataxia and slurred speech after artesunate treatment for falciparum malaria. N. Engl. J. Med. 336:1328. (Pubitemid 27187796)
33. Mithwani, S., et al. 2004. Population pharmacokinetics of artemether and dihydroartemisinin following single intramuscular dosing of artemether in African children with severe falciparum malaria. Br. J. Clin. Pharmacol. 57:146-152. (Pubitemid 38223526)
34. Molyneux, M. E., T. E. Taylor, J. J. Wirima, and A. Borgstein. 1989. Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian children. Q. J. Med. 71:441-459. (Pubitemid 19161768)
35. Moore, C. C., et al. 2009. Treatment of severe sepsis with artemetherlumefantrine is associated with decreased mortality in Ugandan patients without malaria. Am. J. Trop. Med. Hyg. 80:723-728.
36. Muller, I., M. Bockarie, M. Alpers, and T. Smith. 2003. The epidemiology of malaria in Papua New Guinea. Trends Parasitol. 19:253-259. (Pubitemid 36638726)
37. Nau, R., F. Sorgel, and H. Eiffert. 2010. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin. Microbiol. Rev. 23:858-883.
38. Paediatrics Society of Papua New Guinea. 2005. Standard treatment for common illnesses of children in PNG, 8th ed. Paediatrics Society of Papua New Guinea, Port Moresby, Papua New Guinea.
39. Panossian, L. A., N. I. Garga, and D. Pelletier. 2005. Toxic brainstem encephalopathy after artemisinin treatment for breast cancer. Ann. Neurol. 58:812-813. (Pubitemid 41552563)
40. Price, R., et al. 1999. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am. J. Trop. Med. Hyg. 60:547-555. (Pubitemid 29233109)
41. Rogers, W. O., et al. 2009. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar. J. 8:10.
42. Schmuck, G., E. Roehrdanz, R. K. Haynes, and R. Kahl. 2002. Neurotoxic mode of action of artemisinin. Antimicrob. Agents Chemother. 46:821-827. (Pubitemid 34157669)
43. Souppart, C., N. Gauducheau, N. Sandrenan, and F. Richard. 2002. Development and validation of a high-performance liquid chromatography-mass spectrometry assay for the determination of artemether and its metabolite dihydroartemisinin in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 774:195-203. (Pubitemid 34655491)
44. Stergachis, A., R. J. Bartlein, A. Dodoo, J. Nwokike, and S. P. Kachur. 2010. A situational analysis of pharmacovigilance plans in the Global Fund Malaria and U.S. President's Malaria Initiative proposals. Malar. J. 9:148.
45. Taylor, T. E., et al. 2004. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat. Med. 10:143-145. (Pubitemid 38524882)
46. Toovey, S. 2006. Are currently deployed artemisinins neurotoxic? Toxicol. Lett. 166:95-104. (Pubitemid 44291960)
47. Toovey, S., and A. Jamieson. 2004. Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans. R. Soc. Trop. Med. Hyg. 98:261-267. (Pubitemid 38950400)
48. Tran, T. H., et al. 1996. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N. Engl. J. Med. 335:76-83.
49. van Hensbroek, M. B., et al. 1996. A trial of artemether or quinine in children with cerebral malaria. N. Engl. J. Med. 335:69-75.
50. WHO Multicentre Growth Reference Study Group. 2006. Child growth standards: length/height-for-age, weight-forage, weight-for-length, weight-forheight and body mass index-for-age: methods and development. WHO, Geneva, Switzerland.
51. World Health Organization. 2010. Guidelines for the treatment of malaria, 2nd ed. World Health Organization, Geneva, Switzerland.
52. World Health Organization, Communicable Diseases Cluster. 2000. Severe falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 94(Suppl. 1):S1-S90.
53. Zhang, L., S. L. Beal, and L. B. Sheinerz. 2003. Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods. J. Pharmacokinet. Pharmacodyn. 30:405-416. (Pubitemid 38221932)